Skip to main content
. 2015 May 7;9:167. doi: 10.3389/fnins.2015.00167

Figure 2.

Figure 2

Methodological considerations in phMRI studies illustrated in a proposed timeline and considering both “challenge” studies of novel agents and “activation” studies of established agents deployed for the investigation of task paradigms and disease states. NT, Neurotransmiter; PK, pharmacokinetic; ASL, Arterial Spin Labelling; ROI, Region Of Interest.